JPRN-UMIN000021311已完成未知
phase 2 study of the combination therapy, docetaxel and trastuzumab, for advanced extramammary Paget's disease. - phase 2 study of the combination therapy, docetaxel and trastuzumab, for advanced extramammary Paget's disease.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 13
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Have a history of hypersensitivity to components of the chemotherapeutic drugs 2) Women who may possibly be pregnant or pregnant 3) Patients with severe cardiac dysfunction 4) Has known active central nervous system (CNS) metastasis. 5) Has uncontrolled disease that might confound the results of the study, or is not best interest of the subject to participate, in the opinion of the treating investigator.
研究者
相似试验
进行中（未招募）
1 期
A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma - Docetaxel +/- AZD6244 in MelanomaAdvanced metastatic melanomaEUCTR2009-018153-23-GBniversity of Oxford80
已完成
不适用
A phase I and randomised phase II study of docetaxel and RAD001 (Everolimus) in advanced / recurrent or metastatic squamous cell carcinoma of the head and neckAdvanced / recurrent or metastsatic squamous cell carcinoma of the head and neck.squamous cell carcinoma of the head and neckCancerISRCTN73814534niversity College London (UCL) (UK)120
进行中（未招募）
1 期
Phase I/II-StudieKombinationschemotherapie mit Docetaxel und Pemetrexed in der 2nd line-Therapie bei Patienten mit NSCLC, Stadium IIIB und IVEUCTR2005-002832-93-DEStädt. Krankenhaus Martha Maria Halle53
已完成
2 期
A phase II study of TAS-102 and RamucirumabJPRN-jRCT2080224529Taiho Pharmaceutical Co., Ltd.60
已完成
1 期
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for unresectable esophageal squamous cell carcinoma after induction chemothrapynresectable esophageal squamous cell carcinoma after induction chemotherapyJPRN-UMIN000004856Gastroenterologic surgery, Kanazawa university44